Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Download
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
4353919
Reference Type
Technical Report
Subtype
EPA Report
Title
DuPont-24113: FRD-902: Acute dermal toxicity study in rats
Author(s)
Carpenter, C
Year
2007
Publisher
E.I. du Pont de Nemours and Company
Location
Newark, Delaware
Number of Pages
29
Language
English
Abstract
A single dose of FRD-902 was applied to the shaved, intact skin of 5 male and 5 female rats at a dose of 5000 mg/kg of body weight. The application site was covered with a semi-occlusive dressing for 24 hours, after which the test substance was removed. The rats were observed for 14 days following application. The rats were necropsied to detect grossly observable evidence of organ or tissue damage at the end of the 15-day test period.
No deaths occurred. The rats exhibited no clinical signs of systemic toxicity or body weight loss. No erythema or edema was observed on the test site of male rats. All female rats exhibited erythema (score of 2) but no edema on the test site the day after application of the test substance. No erythema was observed in these rats by 2 days after application. Hyperkeratosis was observed on the test site of 8 rats, and ulceration was observed on the test site of 3 rats during the study. All dermal effects cleared by 13 days after application. No gross lesions were present in the rats at necropsy.
Under the conditions of this study, the skin absorption LD50 for FRD-902 was greater than 5000 mg/kg of body weight when applied to the skin of male and female rats for 24 hours.
In accordance with the provisions of Directive 67/548/EEC, classification by the dermal route is not required based on the results of this study
Tags
PFAS
•
GenX Chemicals (CASRN 13252-13-6 and CASRN 62037-80-3)
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity